ImmunityBio's ANKTIVA Now Available To Patients Through Both Commercial And Government Insurance Programs, Also Announced Plans To Expand Its Bladder Cancer Program Globally, Notably In The European Union And India
Portfolio Pulse from Benzinga Newsdesk
ImmunityBio's ANKTIVA has achieved significant market access in the U.S. through commercial and Medicare insurance programs within three months of FDA approval. The company plans to expand its bladder cancer program globally, with regulatory filings initiated in the European Union and India. Additionally, a meeting with the FDA regarding ANKTIVA for Non-Small Cell Lung Cancer (NSCLC) was held in June 2024.
August 12, 2024 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ImmunityBio's ANKTIVA has achieved significant market access in the U.S. and is set for global expansion in the bladder cancer program, with regulatory filings in the EU and India. This progress could positively impact the company's stock in the short term.
The wide availability of ANKTIVA in the U.S. through commercial and Medicare insurance programs is a significant milestone that can drive revenue growth. The global expansion plans, including regulatory filings in the EU and India, further enhance the company's market potential. These developments are likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100